What is the mechanism of action of imipenem?
Imipenem + cilastatin is a beta-lactam antibiotic of the carbapenems class with a broad spectrum of activity. The mechanism of action is similar to the other beta-lactam antibiotics, which is to inactivate the penicillin-binding proteins (PBP) and cause cell wall lysis, or interfere with cell wall formation.
How does imipenem cilastatin work?
It works by killing bacteria. Cilastatin is in a class of medications called dehydropeptidase inhibitors. It works by helping imipenem stay active in your body for a longer period of time. Antibiotics such as imipenem and cilastatin injection will not work for colds, flu, or other viral infections.
How does imipenem inhibit bacterial growth?
Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to penicillin-binding proteins (PBPs).
What is the mechanism of action of meropenem?
Mechanism of Action Meropenem is an antibacterial drug. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to bind penicillin-binding-protein (PBP) targets.
What is the mechanism of action of carbapenems?
Carbapenems act as mechanism-based inhibitors of the peptidase domain of PBPs and can inhibit peptide cross-linking as well as other peptidase reactions. A key factor of the efficacy of carbapenems is their ability to bind to multiple different PBPs (81).
Is imipenem bactericidal or bacteriostatic?
Imipenem is bactericidal (minimal bactericidal concentrations (MBCs] less than twice the MICs). For P. aeruginosa, MBCs of imipenem are less influenced by high inoculum density rather than are MBCs of antipseudomonal penicillins and cephalosporins.
Why cilastatin is added to imipenem?
Because imipenem is rapidly inactivated by renal dehydropeptidase I (DHP-1), it is given in combination with cilastatin (sye” la stat’ in), a DHP-I inhibitor which increases half-life and tissue penetration of imipenem.
Why we use cilastatin with imipenem?
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Renal Dehydropeptidase degrades the antibiotic imipenem. Cilastatin is therefore combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect.
What does imipenem do to bacteria?
Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various Gram-positive and Gram-negative bacteria.
What is the difference between imipenem and meropenem?
Imipenem, the first carbapenem, was first marketed in 1987; meropenem was introduced to the market in 1996. In general, imipenem is more active against Gram-positive cocci while meropenem is more active against Gram-negative bacilli. The agents display similar pharmacokinetics.
Why are carbapenem resistant to beta lactamase?
Their unique molecular structure is due to the presence of a carbapenem together with the beta-lactam ring. This combination confers exceptional stability against most beta-lactamases (enzymes that inactivate beta-lactams) including ampicillin and carbenicillin (AmpC) and the extended spectrum beta-lactamases (ESBLs).
What is the mechanism of action of carbapenem?
What is the function of cilastatin?
Cilastatin is a renal dehydropeptidase inhibitor used to prevent degradation of imipenem. Both medications are used together to treat a variety of infections.
What is imipenem and cilastatin used for?
Written by Cerner Multum. What is imipenem and cilastatin? Imipenem and cilastatin is a combination medicine used to treat severe infections of the heart, lungs, bladder, kidneys, skin, blood, bones, joints, stomach, or female reproductive organs. Imipenem and cilastatin may also be used for purposes not listed in this medication guide.
What is the mechanism of action of cilastatin?
Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4.
What are the possible complications of imipenem/cilastatin toxicity?
More serious hepatic injury from imipenem/cilastatin is rare, but jaundice and liver test abnormalities have been reported in 0.1% of patients in prospective trials of the agent. Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems.